日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

一项针对轻度至中度冠状病毒病2019高危患者的Regdanvimab随机临床试验

Kim, Jin Yong; Săndulescu, Oana; Preotescu, Liliana-Lucia; Rivera-Martínez, Norma E; Dobryanska, Marta; Birlutiu, Victoria; Miftode, Egidia G; Gaibu, Natalia; Caliman-Sturdza, Olga; Florescu, Simin-Aysel; Shi, Hye Jin; Streinu-Cercel, Anca; Streinu-Cercel, Adrian; Lee, Sang Joon; Kim, Sung Hyun; Chang, Ilsung; Bae, Yun Ju; Suh, Jee Hye; Chung, Da Rae; Kim, Sun Jung; Kim, Mi Rim; Lee, Seul Gi; Park, Gahee; Eom, Joong Sik

Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin

接受沙格列汀、西他列汀或维格列汀治疗的 2 型糖尿病患者的二肽基肽酶 4 抑制

Daniel A Tatosian, Ying Guo, Andrea K Schaeffer, Natalia Gaibu, Serghei Popa, Aubrey Stoch, Ronald B Langdon, Eunkyung A Kauh

Prevalence of hypertension and diabetes and coexistence of chronic kidney disease and cardiovascular risk in the population of the republic of moldova

摩尔多瓦共和国人口中高血压和糖尿病的患病率以及慢性肾脏病和心血管风险的共存情况

Codreanu, Igor; Sali, Vera; Gaibu, Sergiu; Suveica, Luminita; Popa, Sergiu; Perico, Norberto; Ene-Iordache, Bogdan; Carminati, Sergio; Feehally, John; Remuzzi, Giuseppe